Pfizer: third-quarter profit rises - above estimates
(CercleFinance.com) - Pfizer reported higher third-quarter profit as the US drugmaker completed its consumer healthcare joint venture deal with GSK.
The New York-based company posted net profit of 7.68 billion dollars, compared with a profit of 4.11 billion dollars a year ago.
In the third quarter, Pfizer recognized an 8.1 billion dollars pre-tax gain upon the completion of its consumer healthcare joint venture deal with GSK
Excluding extraordinary items, Pfizer earned 4.21 billion dollars, or 75 cents per share, from 4.58 billion dollars, or 77 cents a share, in the same period a year ago.
The world's biggest drugmaker saw its sales declined 5% to 12.7 billion dollars, but biopharma revenues jumped by 9% to 10.1 billion dollars.
Pfizer updated its full-year forecast, now expecting adjusted earnings of 2.94 dollars to 3 dollars per share, up from its previous view of 2.76 dollars to 2.86 dollars per share.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The New York-based company posted net profit of 7.68 billion dollars, compared with a profit of 4.11 billion dollars a year ago.
In the third quarter, Pfizer recognized an 8.1 billion dollars pre-tax gain upon the completion of its consumer healthcare joint venture deal with GSK
Excluding extraordinary items, Pfizer earned 4.21 billion dollars, or 75 cents per share, from 4.58 billion dollars, or 77 cents a share, in the same period a year ago.
The world's biggest drugmaker saw its sales declined 5% to 12.7 billion dollars, but biopharma revenues jumped by 9% to 10.1 billion dollars.
Pfizer updated its full-year forecast, now expecting adjusted earnings of 2.94 dollars to 3 dollars per share, up from its previous view of 2.76 dollars to 2.86 dollars per share.
Copyright (c) 2019 CercleFinance.com. All rights reserved.